Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Jokasta Neurosciences Deal Jokasta Neurosciences received a direct license from the University of California, San Francisco (UCSF) for developments with the α-Klotho protein on August 19. The company reported an exclusive license, replacing and expanding previous rights obtained through Unity Biotechnology; the protein candidate JN-0413 remains in the preclinical stage, with the first phase planned to begin in early 2027. The new agreement gives Jokasta exclusive rights to UCSF's intellectual property related to α-Klotho, a protein whose levels decrease with age. The license covers therapy for neurodegenerative diseases and the application of α-Klotho for cognitive and motor function. In May 2019, UCSF granted Unity Biotechnology an exclusive license for certain α-Klotho patents and know-how. In a 2021 agreement, Unity Biotechnology transferred sub-license rights to Jokasta - a license issued based on its contract with UCSF. Jokasta committed to paying an advance, future milestone payments, royalties - sales proceeds - and fulfilling payment obligations to UCSF under Unity's contract. On September 26, 2025, Unity Biotechnology was legally dissolved. After the current deal, Jokasta reported that there are no future milestone payments and royalties under the old agreement with Unity. The choice of α-Klotho is based on published preclinical data, as described in a Nature Aging, July 2026 article, which is not directly referenced here but the research is mentioned. 🔗 Read original →